Generated

CVS Health beats second-quarter earnings estimates and raises 2026 profit guidance

CVS Health reported second-quarter net income of nearly $3 billion, nearly triple the amount posted during the same period last year. The healthcare giant surpassed Wall Street's revenue expectations across all three of its business segments, driven largely by a recovery in its insurance unit, Aetna. Despite the strong results, shares of CVS Health fell more than 6% in morning trading on Wednesday. This decline was attributed to expectations of membership declines in Caremark, its pharmacy benefit manager. CVS Health raised its 2026 adjusted earnings per share guidance to between $7.90 and $8.10, up from a previous outlook of $7.30 to $7.50. The company also announced a new collaboration with Eli Lilly to make its obesity injections Zepbound and Foundayo accessible to eligible patients on the CVS Health app. The company's health services division, which includes Caremark, saw revenue growth of 11.5% year-over-year. However, executives noted that challenges in the federal 340B drug discount program are beginning to pressure the division's earnings.

Sources